AbbVie Inc. $ABBV Stock Sold by Yousif Capital Management LLC

Yousif Capital Management LLC lessened its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 3.0% in the third quarter, according to its most recent filing with the SEC. The firm owned 196,219 shares of the company’s stock after selling 6,150 shares during the quarter. AbbVie comprises approximately 0.6% of Yousif Capital Management LLC’s holdings, making the stock its 24th largest position. Yousif Capital Management LLC’s holdings in AbbVie were worth $51,329,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the stock. BIP Wealth LLC lifted its holdings in shares of AbbVie by 2.3% in the third quarter. BIP Wealth LLC now owns 9,254 shares of the company’s stock valued at $2,421,000 after buying an additional 205 shares during the period. River Street Advisors LLC grew its holdings in AbbVie by 2.2% during the third quarter. River Street Advisors LLC now owns 14,074 shares of the company’s stock worth $3,682,000 after acquiring an additional 297 shares during the period. Parthenon LLC grew its holdings in AbbVie by 0.8% during the third quarter. Parthenon LLC now owns 14,335 shares of the company’s stock worth $3,750,000 after acquiring an additional 120 shares during the period. MLP3 LLC grew its holdings in AbbVie by 8.4% during the third quarter. MLP3 LLC now owns 2,813 shares of the company’s stock worth $736,000 after acquiring an additional 219 shares during the period. Finally, Boomfish Wealth Group LLC raised its position in AbbVie by 4.5% in the third quarter. Boomfish Wealth Group LLC now owns 1,508 shares of the company’s stock worth $394,000 after acquiring an additional 65 shares in the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The U.S. FDA approved a subcutaneous induction regimen for SKYRIZI in adults with moderately to severely active Crohn’s disease. The on-body injector provides a more convenient administration option throughout treatment, while Phase 3 data showed superior clinical remission and endoscopic response versus placebo with no new safety risks. The approval could strengthen SKYRIZI’s commercial position and support AbbVie’s post-Humira growth strategy. FDA approves subcutaneous SKYRIZI induction for Crohn’s disease
• Positive Sentiment: AbbVie’s dividend remains a key defensive attraction. Analysts and financial commentators point to the company’s ability to maintain shareholder payouts despite Humira’s patent loss, supported by growth from SKYRIZI, RINVOQ and other newer products. AbbVie’s dividend after Humira’s patent cliff
• Neutral Sentiment: AbbVie’s Phase 3 INTREPID trial for lutikizumab in hidradenitis suppurativa met its primary endpoint and eight ranked secondary endpoints, including reduced pain and fewer flares. However, reported efficacy was viewed by some analysts as underwhelming relative to competing treatments, leaving the drug’s eventual commercial opportunity uncertain. AbbVie reports Phase 3 INTREPID results for lutikizumab
• Negative Sentiment: Investors are approaching next week’s earnings report cautiously. Erste Group lowered its 2026 EPS estimate to $13.90 from $14.00, slightly below the roughly $13.94 consensus, while a Zacks preview said AbbVie lacks the usual indicators for a likely earnings beat. With the shares trading near their 52-week high and at a premium valuation, results and guidance may need to be strong to sustain momentum. AbbVie earnings preview

Wall Street Analyst Weigh In

A number of brokerages have weighed in on ABBV. Royal Bank Of Canada reissued an “outperform” rating and issued a $280.00 price target on shares of AbbVie in a report on Tuesday, October 13th. Scotiabank lifted their price objective on shares of AbbVie from $280.00 to $320.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 6th. HSBC boosted their target price on shares of AbbVie from $300.00 to $315.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. JPMorgan Chase & Co. increased their target price on shares of AbbVie from $285.00 to $300.00 and gave the company an “overweight” rating in a research note on Thursday, October 8th. Finally, Wolfe Research upgraded shares of AbbVie from a “peer perform” rating to an “outperform” rating and raised their target price for the stock from $235.00 to $300.00 in a report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $279.86.

AbbVie Stock Up 0.2%

Shares of NYSE ABBV opened at $285.66 on Friday. The stock’s fifty day simple moving average is $266.33 and its 200 day simple moving average is $241.77. The stock has a market capitalization of $504.70 billion, a price-to-earnings ratio of 80.69, a PEG ratio of 1.30 and a beta of 0.24. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $291.40.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The business had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the prior year, the business posted $2.97 earnings per share. AbbVie’s revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, analysts anticipate that AbbVie Inc. will post 13.93 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 2.4%. The ex-dividend date is Thursday, October 15th. AbbVie’s payout ratio is presently 195.48%.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.06% of the company’s stock.

AbbVie Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.